Straits Research released its highly anticipated report, “Global Carrier Screening Market Size & Outlook, 2026-2034”. According to the study, the global market size is valued at USD 1.98 billion in 2025 and is projected to expand to USD 6.51 billion by 2034, registering a compound annual growth rate (CAGR) of 14.20%.

Market Dynamics

The global carrier screening market is witnessing significant growth, driven by increasing awareness of genetic disorders and the rising demand for preventive reproductive healthcare. A major driver of the market is the growing adoption of expanded carrier screening panels, which allow couples to identify carrier status for multiple autosomal recessive and X-linked conditions before conception or during early pregnancy. The decreasing cost of next-generation sequencing technologies, coupled with the integration of carrier screening into fertility and prenatal care programs, is further supporting market expansion.

However, the market faces certain restraints related to cost and reimbursement challenges. Carrier screening tests remain relatively expensive in many regions, and inconsistent insurance coverage limits accessibility in low and middle-income countries. This financial barrier restricts the adoption of carrier screening services and slows market growth despite technological advancements. On the other hand, the market presents significant opportunities in the Asia Pacific and Latin America. High prevalence of genetic disorders in these regions, combined with increasing government initiatives, public awareness programs, and investments in genetic testing infrastructure, is expected to boost market penetration. Moreover, the expansion of localized laboratory services and partnerships with fertility and healthcare providers further enhances the growth potential.

Market Highlights

• Type: The expanded carrier screening segment dominated the market in 2025.
• Technology: The polymerase chain reaction segment is estimated to grow at the fastest pace with a CAGR of 15.62%.
• Medical Condition: The hematology segment dominated the market with a revenue share of 36.13% in 2025.
• End Use: The laboratories segment dominated the market, accounting for 42.49% share in 2025.